Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1297-1301

  Citterio, G ^a,b   Pellegatta, F ^a   Di Lucca, G ^a   Fragasso, G ^a   Scaglietti, U ^a   Pini, D ^a   Fortis, C ^a   Tresoldi, M ^a   Rugarli, C ^a  

^a Neurological Unit   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cardiovascular toxicity; Interleukin 2; Nitrate; Nitric oxide; Nitrite

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; NITRATE; NITRIC OXIDE; NITRITE; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; MALE; MELANOMA; PRIORITY JOURNAL; SPECTROPHOTOMETRY; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTOLIC BLOOD PRESSURE;

EID: 0029842333     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.533     Document Type: Article

References (26)

1. BALCH CM, HOUGHTON AN AND PATERS LJ. (1993). Cutaneous melanoma. In Cancer. Principles and Practice of Oncology, De Vita VT Jr, Hellman S and Rosenberg SA. (eds) pp. 1612 1661. JB Lippincott: Philadelphia.
2. BESANA C, BORRI A, BUCCI E, CITTERIO G, DI LUCCA G, FORTIS C, MATTEUCCI P, TOGNELLA S, TRESOLDI M, BAIOCCHI C, LANDONIO G, GHISLANDI E AND RUGARLI C. (1994). Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon. Eur. J. Cancer, 30A, 1292 1298.
3. CIFONE MG, FESTUCCIA C, CIRONI L, CAVALLO G, CHESSA MA, PENSA V AND TUBARO E. (1994). Induction of the nitric oxide-synthesizing pathway in fresh and interleukin-2-cultured rat natural killer cells. Cell Immunol., 157, 181 194.
4. COX GW, MELILLO G, CHATTOPADHYAY U, MULLET D, FERTEL RH AND VARESIO L. (1992). Tumor necrosis factor-alpha-dependent production of reactive nitrogen intermediates mediates IFN-gamma plus IL-2-induced murine macrophage tumoricidal activity. J. Immunol., 149, 3290 3296.
5. DE BELDER AJ, RADOMSKY MW AND WHY HJF. (1993). Nitric-oxide synthase activities in human myocardium. Lancet, 431, 84 85.
6. DI LUCCA G, CITTERIO G, FRAGASSO G, ROSSETTI E, SC AGLIETTI U, TRESOLDI M, RUGARLI C AND CHIERCHIA SL. (1995). Assessment of interleukin-2-induced cardiovascular toxicity by echocardiography. Eur. J. Cancer, 31 A, S123.
7. FINKEL MS, ODDIS CV, JACOB TD, WATKINS SC, HATTLER BG AND SIMMONS RL. (1992). Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257, 387 389.
8. FOPPOLI M, CITTERIO G, POLASTRI D AND GUERRIERI R. (1995). The feasibility of repetitive courses of high-dose continuous intravenous infusion interleukin-2 and subcutaneous alpha-interferon with polichemotherapy in advanced malignant melanoma. Tumori, 81, 102 106.
9. GREEN LC, WAGNER DA, GLOGOWSKI J, SKIPPER PL, WISHNOK JS AND TANNEBAUM SR. (1982). Analysis of nitrate, nitrite, and 15Nénitrate in biological fluids. Ann. Biochem., 126, 131 138.
10. HIBBS JB JR, WESTENFELDER C, TAINTOR R, VAVRIN Z, KABLITZ C, BARANOWSKI RL, WARD JH, MENLOVE RL, MCMURRAY MP AND KUSIINER JP. (1992). Evidence for cytokine-inducible nitric-oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest., 89, 867 877.
11. KILBOURN RG, FONSECA GA, GRIFFITH OW, EWER M, PRICE K, STRIEGEL A, JONES E AND LOGOTHETIS CJ. (1995). NG-metyl-L-arginine, an inhibitor of nitric oxide synthase. reverses interleukin-2-induced hypothension. Crit. Care Med., 23, 1018 1024.
12. LINEHAN WM, SHIPLEY WU AND PARKINSON DR. (1993). Cancer of the kidney and ureter. In Cancer. Principles and Practice of Oncology. De Vita VT Jr, Hellman S and Rosenberg SA. (eds) pp. 1023 1042. JB Lippincott: Philadelphia.
13. MARGOLIN KA, RAYNER AA, HAWKINS MJ, ATKINS MB, DUTCHER JP, FISHER RI, WEISS GR, DOROSHOW JH, JAFFE HS AND ROPER M. (1989). Interleukin-2 and lymphokyne activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol., 7, 486-498.
14. MEYER J, LENTZ CW AND STOTHERT JC JR. (1994). Effects of nitric oxide synthesis inhibition in hyperdynamic endotoxemia. Crit. Care Med., 22, 306-312.
15. MILES D, THOMSEN L, BALKWILL F, THAVASU P AND MONCADA S. (1994). Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2. Eur. J. Clin. Invest., 24, 287-290.
16. MONCADA S AND HIGGS A. (1993). The L-arginine-nitric oxide pathway. N. Engl. J. Med., 329, 2002-2012.
17. MONCADA S, PALMER RMJ AND HIGGS EA. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43, 109-142.
18. OCHOA JB, CURTI B, PEITZMAN AB, SIMMINS RL, BILLIAR TR, HOFFMAN R, RAULT R, LONGO DL, URBA WJ AND OCHOA AC. (1992). Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J. Natl Cancer Inst., 84, 864-867.
19. OSANTO S, CLUITMANS FHM, FRANKS CR, BOSKER HA AND CLETON FJ. (1988). Myocardial injury after interleukin-2 therapy. Lancet, 2, 48.
20. PAULUS WJ, VANTRIMPONT PJ AND SHAM AM. (1994). Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation, 89, 2070-2078.
21. PETROS A, LAMB G AND LEONE A. (1994). Effects of nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res., 28, 34-39.
22. RABER J AND BLOOM FE. (1994). IL-2 induces vasopressin release from the hypothalamus and the amygdala: role of nitric oxide-mediated signaling. J. Neurosci., 14, 6187-6195.
23. TAYLOR-ROBINSON AW, LIEW FY, SEVERN A, XU D, MCSORLEY SJ, GARSIDE P AND PADRON J. (1994). Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur. J. Immunol., 24,980-984.
24. WANG P, BA ZF AND CHAUDRY IH. (1994). Nitric oxide. To block or enhance its production during sepsis? Arch. Surg., 129, 1137-1143.
25. WHITE RL, SCHWARTZENTRUBER DJ, GULERIA A, MACPHARLANE MP, WHITE DE, TUCKER E AND ROSENBERG SA. (1994). Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer, 74, 3212-3222.
26. WORLD HEALTH ORGANIZATION. (1979). Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No 48. WHO: Geneva.